Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Ph I IMGN853 & rucaparib for recurrent endometrial, ovarian, fallopian tube or primary peritoneal ca

Protocol: OSU-18007

Full Title

Phase I study of mirvetuximab soravtansine (IMGN853) and rucaparib for recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer

Gynecologic Cancers Endometrial Cancer Ovarian Cancer Peritoneal Cancer Gastrointestinal Cancers